In a prospective registry of newly diagnosed pediatric CNS tumor patients (age 21 and younger), 33% (5/15) of patients diagnosed with IDH-mutant high-grade gliomas were part of this newly identified group (data not shown). Here, IDH2 is linked to central nervous system cancer.